Blue Bees Therapeutics

Executive Summary

Blue Bees Therapeutics is a French biotechnology company founded in 2022, leveraging a breakthrough technology from CEA Paris-Saclay to develop first-in-class immunomodulatory proteins for cancer treatment. Its lead candidate, BB101, is a bi-specific receptor/co-receptor engaging antibody designed to stimulate anti-tumor immune responses by targeting specific pathways. The company’s platform has the potential to generate a pipeline of novel immunotherapies, addressing significant unmet needs in oncology. As a preclinical-stage company, Blue Bees is positioned to advance BB101 toward clinical development, though it currently has no disclosed funding or partnership details, reflecting its early stage.

Upcoming Catalysts (preview)

• Q2 2027Completion of IND-enabling studies for BB10160% success
• Q4 2026Series A financing round50% success
• Q3 2026Presentation of preclinical efficacy data at a major conference70% success